Clinical trials: Bronchiectasis
Cystic Fibrosis, Bronchiectasis
Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements
The impact of high-frequency chest wall oscillation therapy on spirometry values (Forced Expiratory Volume, Forced Vital Capacity, Peak Expiratory Flow, Forced Expiratory Flow and Tidal Volume is investigated during use of…
- Trial name
- NCT03534986
- Testing
- International Biophysics AffloVest, Hill-Rom The Vest, Respirtech inCourage
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- International Biophysics Corporation
Bronchiectasis, Adenosine Deaminase Deficiency
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)
This observational study was designed as a prospective epidemiological screening study. Patients who applied to the centers participating in the study, bronchiectasis was detected on at least one computed tomography of the lungs…
- Conditions
- Bronchiectasis, Adenosine Deaminase Deficiency, Pulmonary Disease
- Trial name
- NCT05300347
- Testing
- adenosine deaminase enzyme deficiency test
- Where
- Turkey (Türkiye)
- Volunteers
- 500 people
- Sponsor
- TRPHARM
Bronchiectasis
Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis
The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and gram-negative airway infection. Participants received two 28-day courses of either Aztreonam for Inhalation Solution (AZLI) or placebo taken 3…
- Trial name
- AIR-BX1 (NCT01313624)
- Testing
- AZLI
- Where
- 60 sites in United States, Australia and 1 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
Non-cystic Fibrosis Bronchiectasis
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens…
- Trial name
- NCT07048262
- Testing
- CSL787, Nebulizer
- Where
- 13 sites in Australia, Japan
- Volunteers
- 180 people
- Sponsor
- CSL Behring
Adolescent Asthma
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis
- Trial name
- NCT06775340
- Testing
- RSS0343 Tabella
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Bronchiectasis
Inspiratory Flow and Volumes in Bronchiectatics
Adequate administration of drugs via dry powder inhalers is dependent on adequate inspiratory flow rates and volumes. These vary according to the device being used and its resistance.
- Trial name
- NCT00656565
- Where
- Australia
- Volunteers
- 15 people
- Sponsor
- Syntara
Bronchiectasis
Inhalation Flow Rate-study
Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.
- Trial name
- NCT02563197
- Testing
- T-326 Inhaler
- Where
- 10 sites in Germany
- Volunteers
- 33 people
- Sponsor
- Bayer
Cystic Fibrosis, Non-Cystic Fibrosis Bronchiectasis
A Clinical Study to Investigate Safety, Tolerability and Distribution of CHF 6333 After One or After Repeated Inhalation in Patients With Cystic Fibrosis (CF) and in Patients With Non Cystic Fibrosis (NCFB) Bronchiectasis
CHF 6333 is a medicinal product on development for the treatment of cystic fibrosis and non-CF bronchiectasis and undergoing clinical testing. It has not yet been approved by the authorities for the treatment of these diseases.
- Trial name
- NCT04010799
- Testing
- CHF 6333
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Non-cystic Fibrosis Bronchiectasis
A Clinical Study of RSS0343 in Healthy Subjects
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of RSS0343 following multiple oral doses in healthy subjects, as well as its effects on the QT/QTc interval.
- Trial name
- NCT07289464
- Testing
- RSS0343 Tablets
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Asthma, Respiratory Candidiasis
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts.
- Conditions
- Asthma, Respiratory Candidiasis, Respiratory Aspergillosis, COPD
- Trial name
- NCT03745196
- Testing
- PC945
- Where
- 4 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pulmocide Ltd
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited
Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization
First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients
The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and…
- Conditions
- Bronchiectasis Adult, Bronchiectasis With Pseudomonas Aeruginosa Colonization, Bacterial Infections
- Trial name
- NCT07708116
- Testing
- CTX-187
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Centauri Therapeutics Limited
Bronchiectasis With Pseudomonas Aeruginosa Colonization
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
AZD0292 is a bispecific IgG1k mAb being evaluated for the prevention of exacerbations in bronchiectasis patients chronically colonized with PsA.
- Trial name
- CLEAR (NCT07088926)
- Testing
- AZD0292
- Where
- 186 sites in United States, Argentina and 23 more
- Volunteers
- 435 people
- Sponsor
- AstraZeneca
Bronchiectasis
Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis
The purpose of this study is to determine whether potentiating the cystic fibrosis transmembrane conductance regulator (CFTR) with QBW251 in patients with bronchiectasis will demonstrate clinical safety and efficacy related to…
- Trial name
- NCT04396366
- Testing
- QBW251
- Where
- 14 sites in China, Germany and 2 more
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Bronchiectasis
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
This study is designed to find out how effective and safe a new drug, GSK3862995B, is for adult participants with bronchiectasis, a chronic lung disease.
- Trial name
- NCT07201051
- Testing
- GSK3862995B
- Where
- 134 sites in United States, Argentina and 10 more
- Volunteers
- 363 people
- Sponsor
- GlaxoSmithKline
Bronchiectasis
Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis
No gold standard therapy exists for clearing mucus from the airways of patients with bronchiectasis. While rhDNase has a proven place in the treatment of cystic fibrosis (CF), it failed to improve Forced expiratory volume in one…
- Trial name
- NCT00669331
- Testing
- Inhaled mannitol, Matched control
- Where
- 83 sites in United States, Argentina and 7 more
- Volunteers
- 485 people
- Sponsor
- Syntara
Bronchiectasis
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ).
- Trial name
- NCT05846230
- Testing
- BI 1291583
- Where
- 103 sites in United States, Australia and 20 more
- Volunteers
- 268 people
- Sponsor
- Boehringer Ingelheim
Non Cystic Fibrosis Bronchiectasis
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)
This study (ARD-3150-1202, ORBIT-4) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic…
- Trial name
- NCT02104245
- Testing
- Ciprofloxacin dispersion for inhalation
- Where
- 95 sites in United States, Australia and 14 more
- Volunteers
- 304 people
- Sponsor
- Aradigm Corporation
Non Cystic Fibrosis Bronchiectasis
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)
This study (ARD-3150-1201, ORBIT-3) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic…
- Trial name
- NCT01515007
- Testing
- Ciprofloxacin dispersion for inhalation
- Where
- 109 sites in United States, Australia and 14 more
- Volunteers
- 278 people
- Sponsor
- Aradigm Corporation
Non Cystic Fibrosis Bronchiectasis
Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)
The objective of the trial was to investigate the effect of the use of inhaled CMS, administered b.i.d. via a specific nebuliser for 12 months, compared to placebo in subjects with NCFB chronically infected with P.
- Trial name
- PROMIS-I (NCT03093974)
- Testing
- CMS
- Where
- 85 sites in Australia, Belgium and 10 more
- Volunteers
- 377 people
- Sponsor
- Zambon SpA